• Radiopharm reported interim Phase 2b imaging-trial results for RAD 101 in suspected recurrent brain metastases, with 90% concordance between PET imaging and MRI among 20 evaluable patients.
• The company positioned the readout as supporting a differentiated approach to addressing diagnostic uncertainty that can affect treatment decisions in neuro-oncology.
• RAD 101 has FDA Fast Track Designation, which may support a faster development and review pathway if subsequent data remain supportive.
• Radiopharm said final results from the 30-patient study are expected by June, which it plans to use to inform a potential pivotal trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-033188), on March 24, 2026, and is solely responsible for the information contained therein.